Table 3.
Noncancer drug repurposing candidates for HAT, HMT, HDM and BET inhibition.
| Drug | Approved for | Epigenetic Target | Cancer Model |
|---|---|---|---|
| Anarcadic Acid | Anti-inflammatory and radio-sensitization activities | Ep300 and Tip60 | Cervical Cancer [79], Myeloid Leukemia, T-Cell Lymphoma, Lung Cancer, Prostate Cancer [80] |
| Clorgyline | MAO inhibitor | LSD1 | Bladder Cancer, Colon Cancer, Leukemia [81] |
| Garcinol | Antioxidant (not approved) | Ep300 and KAT2B | Cervical Cancer [82], Breast Cancer [83], Hepatocellular Carcinoma [84], Esophageal Carcinoma [85] |
| Geranylgeranoic Acid | Natural Compound (not approved) | LSD1 | Neuroblastoma [86] |
| Nitroxoline | Urinary antibacterial agent | BRD4 | Mixed-Lineage Leukemia [87] |
| Pargyline | Irreversible selective MAO-B and antihypertensive | LSD1 | Prostate Cancer [88] |
| Plumbagin | Natural Compound (not approved) | KAT3B/p300 | Liver Carcinoma [89] |
| Ribavirin | RSV infections and Hepatitis C | EZH2 | Solid Tumors [90,91,92] |
| Tranylcypromine | Depression, Dysthymic disorder, atypical depression, panic and phobic disorders | LSD1 | Glioblastoma Multiforme [93], Sarcomas [94], Embryonal Carcinoma [95] |